These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 9175283

  • 1. Maximal androgen blockade versus total androgen suppression.
    Dumez H, Van Poppel H, Baert L, Paridaens R.
    Acta Urol Belg; 1997 Mar; 65(1):49-54. PubMed ID: 9175283
    [Abstract] [Full Text] [Related]

  • 2. Endocrine therapy: where do we stand and where are we going?
    Schröder FH.
    Cancer Surv; 1991 Mar; 11():177-94. PubMed ID: 1841751
    [Abstract] [Full Text] [Related]

  • 3. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T, Shimamura M, Miyazaki K, Nishino A, Namiki M.
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [Abstract] [Full Text] [Related]

  • 4. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ.
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [Abstract] [Full Text] [Related]

  • 5. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J.
    Eur Urol; 1997 Aug; 32 Suppl 3():78-80. PubMed ID: 9267790
    [Abstract] [Full Text] [Related]

  • 6. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T.
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [Abstract] [Full Text] [Related]

  • 7. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 11. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H, Messing EM, Chang C.
    Prostate; 2004 Dec 01; 61(4):332-53. PubMed ID: 15389811
    [Abstract] [Full Text] [Related]

  • 12. Endocrine therapy for prostate cancer.
    Labrie F.
    Endocrinol Metab Clin North Am; 1991 Dec 01; 20(4):845-72. PubMed ID: 1778180
    [Abstract] [Full Text] [Related]

  • 13. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM, Chertin B, Fridmans A, Farkas A, Belanger A, Hartman H, Labrie F.
    Prostate Cancer Prostatic Dis; 2009 Dec 01; 12(1):100-3. PubMed ID: 18574491
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Science behind total androgen blockade: from gene to combination therapy.
    Labrie F, Bélanger A, Dupont A, Luu-The V, Simard J, Labrie C.
    Clin Invest Med; 1993 Dec 01; 16(6):475-92. PubMed ID: 8013153
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined androgen blockade: an update.
    Klotz L.
    Urol Clin North Am; 2006 May 01; 33(2):161-6, v-vi. PubMed ID: 16631454
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.